Literature DB >> 18297439

Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns.

Yusuke Okuwaki1, Takahide Nakazawa, Akitaka Shibuya, Koji Ono, Hisashi Hidaka, Masaaki Watanabe, Shigehiro Kokubu, Katsunori Saigenji.   

Abstract

BACKGROUND: The pathogenesis of frequent intrahepatic recurrence of hepatocellular carcinoma (HCC) after surgical resection or local ablation therapy remains uncertain. Risks and patterns of intrahepatic distant recurrence (IDR) of a single, primary HCC lesion after radiofrequency (RF) ablation were examined.
METHODS: Ninety patients with a single primary HCC lesion of less than 3 cm who had complete RF ablation were enrolled in the study. Risk factors for IDR and the patterns of IDR after RF ablation were analyzed.
RESULTS: The median follow-up was 37.4 months. IDR was observed in 44 (48.9%) patients. The cumulative rate of IDR was 10.4%, 52.5%, and 77.0% at 1, 3, and 5 years, respectively. Univariate analysis revealed that a pretreatment serum alpha-fetoprotein (AFP) level of > or =50 ng/ml (P = 0.0324), a des-gamma-carboxy prothrombin (DCP) level of > or =40 mAu/ml (P = 0.006), an ablative margin of <5 mm of the ablation zone (P = 0.0306), and a prothrombin time of <70% (P = 0.0188) were related to IDR. A multivariate stepwise Cox proportional hazards regression model revealed that pretreatment serum AFP and DCP level and the ablative margin were independent risk factors for IDR pretreatment. Serum DCP level > or = 40 mAu/ml (P = 0.025), local tumor progression (P = 0.011), and ablative margin < 5 mm (P = 0.024) were related to multiple IDR.
CONCLUSIONS: HCC patients with high serum AFP or DCP before RF ablation should be carefully followed up to monitor any IDR. A sufficient ablative margin in RF ablation for HCC is required to prevent IDR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297439     DOI: 10.1007/s00535-007-2123-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.

Authors:  K N Khan; H Yatsuhashi; K Yamasaki; M Yamasaki; O Inoue; M Koga; M Yano
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin.

Authors:  Takahide Nakazawa; Shigehiro Kokubu; Akitaka Shibuya; Koji Ono; Masaaki Watanabe; Hisashi Hidaka; Takeshi Tsuchihashi; Katsunori Saigenji
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

4.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

Authors:  Riccardo Lencioni; Dania Cioni; Laura Crocetti; Chiara Franchini; Clotilde Della Pina; Jacopo Lera; Carlo Bartolozzi
Journal:  Radiology       Date:  2005-01-21       Impact factor: 11.105

5.  Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.

Authors:  J Belghiti; Y Panis; O Farges; J P Benhamou; F Fekete
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

Review 6.  Hepatocellular carcinoma.

Authors:  K Okuda
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

7.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

8.  Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

Authors:  K Tarao; S Takemiya; S Tamai; Y Sugimasa; S Ohkawa; M Akaike; H Tanabe; A Shimizu; M Yoshida; A Kakita
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

9.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

10.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

View more
  25 in total

1.  A special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation.

Authors:  Qing-Yu Liu; Dong-Ming Lai; Chao Liu; Lei Zhang; Wei-Dong Zhang; Hai-Gang Li; Ming Gao
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior.

Authors:  Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhi-Hong Xian; Hua Yu; Zhen Zhu; Feng Shen; Meng-Chao Wu; Wen-Ming Cong
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

3.  Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report.

Authors:  Yusuke Okuwaki; Takahide Nakazawa; Hisashi Hidaka; Akitaka Shibuya; Wasaburo Koizumi
Journal:  J Med Case Rep       Date:  2012-01-26

4.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

Review 5.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis.

Authors:  Hui-Ming Yi; Wei Zhang; Xi Ai; Kai-Yan Li; You-Bin Deng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 7.  Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Authors:  Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Gisèle N'Kontchou; Pierre Nahon; Véronique Grando; Valérie Bourcier; Sandrine Barge; Michel Beaugrand; Jean-Claude Trinchet; Olivier Seror
Journal:  Hepat Oncol       Date:  2014-12-11

Review 8.  Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.

Authors:  Zlatko Devcic; Mohamed Elboraey; Lucas Vidal; Kabir Mody; Denise Harnois; Tushar Patel; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 9.  Role of stereotactic body radiation therapy for hepatocellular carcinoma.

Authors:  Naoko Sanuki; Atsuya Takeda; Etsuo Kunieda
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 10.  [Radiofrequency ablation of hepatocellular carcinoma].

Authors:  Gerlig Widmann; Peter Schullian; Reto Bale
Journal:  Wien Med Wochenschr       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.